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Prognostic value of thymidylate synthase expression in colorectal cancer
Anna Patla, Janusz Pawlęga
A im . The aim o f the study was to define the prognostic value o f thymidylate synthase (TS) expression in colorectal cancer 
(CRC), and its role as a predictor o f the chemotherapeutic benefit in patients treated with fluorouracil (5-FU).
M a t e r i a l  a n d  m e t h o d s .  TS expression was immunohistochemically assessed on primary tumor archival specimens from  
120 patients with CRC.
R e s u l t s .  For the entire study population the univariate analysis revealed that TNM  stage, surgical margin, vessel invasion, 
and TS expression were significant prognostic factors. In a subgroup treated with 5-FU (n=98) overall survival correlated with 
tumor location, TNM  stage, surgical margin, and TS expression. Multivariate analysis demonstrated that tumor stage, TNM  
stage, and TS expression were independent prognostic factors. In the subgroup treated with 5-FU only tumor location, tumor 
stage, and TNM  stage correlated with survival.
C o n c l u s i o n s .  TS expression in primary tumors was a significant, independent prognostic factor in colorectal cancer. The 
evaluation o f its predictive role requires further investigations.
Znaczenie syntetazy tymidylowej w rokowaniu u chorych z rakiem jelita grubego
Cel. Celem pracy było określenie wartości prognostycznej i predykcyjnej ekspresji syntetazy tymidylowej (TS) w raku jelita 
grubego.
M a t e r i a ł  i m e t o d y  Ekspresję TS oznaczano immunohistochemicznie w bloczkach parafinowych z  guzów pierwotnych 
u 120 chorych z  rakiem jelita grubego.
Wynik i .  Analiza jednocechowa wykazała, ze w grupie 120 chorych na całkowite przeżycie wpływały istotnie: zaawansowanie 
procesu nowotworowego, radykalnośc mikroskopowa zabiegu, obecność zatorów z  komórek nowotworowych w naczyniach 
oraz charakter ekspresji TS. W  grupie 98 chorych leczonych chemicznie fluorouracylem na przeżycie wpływały istotnie: 
lokalizacja guza, zaawansowanie procesu, radykalnośc mikroskopowa zabiegu oraz charakter ekspresji TS. Analiza 
wielocechowa wykazała, że głębokość nacieku raka, stopień zaawansowania wg TN M  oraz charakter ekspresji TS są 
istotnymi niezależnymi czynnikami rokowniczymi. W  grupie chorych leczonych fluorouracylem jedynie lokalizacja nowotworu, 
głębokość nacieku i zaawansowanie procesu nowotworowego są niezależnymi istotnymi czynnikami rokowniczymi. 
W n io s k i .  Charakter ekspresji TSjest istotnym, niezależnym czynnikiem rokowniczym wraku jelita grubego. Określenie roli 
predykcyjnej TS wymaga dalszych badań.
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Introduction
Colorectal cancer is one of the most common cancer sites 
diagnosed throughout the world, accounting for approx.
10% of all incident cases [1]. About 50-60% of patients 
are cured by surgery and adjuvant chemotherapy. The 
remaining group will, sooner or later, need palliative 
chem otherapy [2, 3]. The most common chem othera­
peutic agent in the treatm ent of colorectal cancer is still 
fluorouracil. The efficiency of this treatm ent is similar to 
the treatm ent with new antifolate agents, like ralitrexed
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(Tomudex) or capecitabine (Xeloda), depends on the 
activity of thymidylate synthase (TS) [2, 4]. This enzyme is 
responsible for the provision of thymidylate required for 
DNA synthesis and repair [2, 5].
Multiple studies have shown that patients with high 
levels of intratumoral TS expression in their cancers have 
a significantly worse clinical outcome and worse response 
to fluoropyrimidine-containing regimens as compared to 
patients with cancers of a relatively low intracellular level. 
However, the results of these studies are not consistent. 
Currently, only the stage of disease is widely accepted as 
a prognostic factor [6, 7].
In the present investigation, we have retrospectively 
examined the prognostic value of thymidylate synthase
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expression in primary colorectal cancer, and the role of 
this expression as a predictor of the chemotherapeutic 
benefit in patients treated with fluorouracil.
Material and methods
Tumor specimens examined for TS expression were obtained 
from 120 patients with colorectal cancer, who were diagnosed 
between 1992 to 2001. Their characteristics according to sex, 
age, localization of tum or, histology and grading, TNM and 
Dukes classification, microscopic radical margin of surgery and 
vessel invasion are listed in Table I. Mean duration of follow-up 
was 28.6 months (range: 0.3 -  114 months; median: 28 months), 
from August 1992 to March 2003.
Among 120 patients after radical surgery of the primary 
tumor 98 (81.7%) were treated with 5-FU-based chemotherapy 
regimens (45 were treated with chemo-radiotherapy in 1999­
2001; 36 with adjuvant chemotherapy and 17 as palliation in 
dissem inated disease). 61 patients received leucovorin- 
modulated 5-fluorouracil, 25 patients 5-FU plus leucovorin and 
levamisol, and 12 patients were treated with 5-FU and levamisol.
Table I. C haracteristics of the group of 120 patients with colorectal 
cancer treated between the years 1992 and 2001
Characteristic No. of patients % of patients
Sex
Male 74 62%
Female 46 38%
Age (median age 59,4 years)
< 60 years 64 53.3%
> 60 years 56 46.7%
Localization
colon 42 35%
rectum 78 65%
Histology
Adenocarcinoma 117 97.5%
other 3 2.5%
Tumor differentiation
G1 63 52.5%
G2 56 46.7%
G3 1 0.8%
Tumor size pT
pT2 12 10%
pT3 72 60%
pT4 36 30%
Lymph node metastases pN
pN0 64 53.3%
pN1 39 32.5%
pN2 17 14.2%
Distant metastases
M0 101 84.2%
M1 19 15.8%
Dukes’ stage / TNM stage
A  / I° 4 3.3%
B / II° 52 43.3%
C / III° 45 37.5%
D / IV° 19 15.8%
Radical resection margin
yes 73 60.8%
no 47 39.2%
Vessel invasion
no 96 80%
yes 24 20%
12 patients with D ukes A  and B cancer were w ithout any 
adjuvant treatment.
TS i m m u n o h i s t o c h e m i c a l  a n a l y s i s
Paraffin-embedded, formalin fixed specimens of the resected 
tum ors were analyzed immunohistochemically [2-4, 6]. Two 
sections (4 pm thick), taken from different parts of the primary 
tum or were analyzed for TS expression.
Tissue specimens were first deparaffinized in 100% xylene 
and rehydrated through graded alcohol solutions. Endogenous 
peroxidase activity was inhibited by incubating the slides in 3% 
hydrogen peroxidase for 10 minutes, followed by a 5-minute 
rinse in dH 2O. The slides were heated in a microwave oven in 
EDTA, pH  8.0, and stored in TBS (Tris-buffered saline) and 
proteinase K. The tissues were incubated for 60 minutes with TS- 
106 (m ouse m onoclonal antibody, Chemicon International, 
Temecula, CA 92590) at room tem perature at a 1:50 dilution. 
The slides were washed with TBS and then incubated in DAKO 
EnVision+TM, Peroxidase Mouse complex (DAKO Corporation, 
USA) for 30 minutes. The slides were again washed a few times 
with TBS and then incubated with A EC Substrate-chromogen 
system (DAKO AEC) for 10 minutes. Following another wash 
cycle, the tissues were counter-stained with hematoxilin 
(DAKO). The slides were rinsed and closed in glicerogel.
T i s s u e  e v a l u a t i o n
Each slide was examined for intensity and staining pattern by two 
investigators, who were blinded to  all clinical information. 
D iscrepant scores (about 5% of cases) w ere resolved by 
consensus.
Intensity scores ranged from 0 to 3 (0=no staining, 1=trace 
staining, 2=definite staining of light to m oderate intensity, and 
3=bright intensity). The staining pattern was either F (focal) 
or D  (diffuse). Samples with 50% or fewer malignant cells 
stained at the assigned intensity level were considered F  (0=less 
than 25% cells stained, 1=25-50% cells stained). Samples with 
more than 50% of stained cells were scored as D  (2=50-75% 
cells and 3=m ore than 75% cells stained). Examples of the TS 
staining pattern are presented in Figures 1-4.
S t a t i s t i c a l  a n a l y s i s
The outcome variable was overall survival (OS) with death from 
any cause as an end point. Follow-up time was measured from 
the date of surgery.
The analysis was performed for the entire study population 
(n=120) and in the subgroup treated with fluorouracil-based 
chemotherapy at any time (n=98). Owing to the relatively small
Figure 1. The focal TS staining pattern  (TS=0)
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Figure 2. The focal TS staining pattern  (TS=1)
Figure 3. The diffuse TS staining pattern  (TS=2)
numbers of patients treated with chemo-radiotherapy, adjuvant 
and palliative chemotherapy we did not perform the analysis in 
these particular subgroups. Survival distributions were estimated 
using the Kaplan-M eier method.
In the univariate analysis the possible relationships between 
overall survival and age, sex, localization, histological grading, 
TNM and D ukes’ stage, the microscopic radical margin of 
surgery, vessel invasion, TS staining intensity and pattern were 
examined by log-rank test. Multivariate analysis was performed 
using Cox’s regression model. All P  values below 0.05 were 
considered statistically significant.
Results
In the univariate analysis for the entire study population 
(n=120) overall survival was significantly linked to Dukes’ 
and TNM stage, the microscopic radical margin of 
surgery, the vessel invasion and the staining pattern of 
TS (p<0.05 -  Table II). Multivariate analysis showed that 
only the stage and the staining pattern of TS remained as 
the significant prognostic factors (Table III).
In the subgroup treated with 5-FU-based therapy at 
any time (n=98) the univariate analysis revealed the 
prognostic importance of localization, TNM and Dukes’ 
stage, the microscopic radical margin of surgery and the 
staining pattern of TS (Table II). By multivariate analysis 
localization, TNM and D ukes’ stage rem ained as 
important prognostic factors of survival (p<0.05). The 
staining pattern of TS had no significant prognostic value 
in this group (p = 0.0853, Table III).
Discussion
In 1994 Johnston et al. [8] were the first to suggest that 
the level of TS expression in primary colorectal cancer 
may be of prognostic importance. During the next 10 
years at least 28 studies concerning this problem were 
published [2-29]. 16 of them confirmed the observations 
of Johnston et al. [2, 4-6, 8, 9, 11, 12, 14-16, 18, 21, 23, 26, 
28].
The results of our study confirm that the level of TS 
expression in primary colorectal cancer correlates with 
survival. Patients with a low level of TS have a better 
overall survival com pared with patients with high TS 
levels. This observation was restricted only to the TS 
diffuse staining pattern  (Figure 5 and 6). Similarly as 
Gonen et al. [18] and Allegra et al. [2] we were unable to 
identify the prognostic role of TS staining intensity. 
Multivariate analysis has demonstrated that the ability 
of the TS diffuse staining pattern to predict survival was 
independent of the tumor size and the stage of disease.
The results of our investigation seem to be resemble 
most those presented by Allegra et al. [2]. They assessed 
the TS staining pattern  immunohistochemically and 
divided patients into two groups with more or less than 50 
% of cancer cells with TS expression (diffuse vs. focal TS 
staining pattern). Similarly, TS expression was detected in 
the primary tumors with the use of TS 106 monoclonal 
antibody.
Gonen and others have estimated TS expression in 
frozen samples of liver m etastases with the use of 
a polyclonal antibody [18]. Due to those technical diffe­
rences the results confirmed the prognostic significance of 
thymidylate synthase in colorectal cancer.
The Edler et al. study revealed the prognostic value 
of TS in the group of 862 patients with Dukes’ B and C 
colorectal cancer [6]. The m aterial and methods were 
similar as in our study. Similarly, most of patients had 
high TS level that correlated with overall survival. As in 
our investigation Edler was not able to prove the prog­
nostic role of TS expression in the subgroup of patients
Figure 4. The diffuse TS staining pattern  (TS=3)
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Table II. Univariate overall survival analysis for examined param eters
Parameter
n
All patients (n=120) 
OS (%) P n
Chemotherapy group (n=98) 
OS (%) P
Sex
Male 74 63 .5160 58 64 .9041
Female 46 62 40 59
Age
< 60 years 64 64 .2027 56 61 .6604
> 60 years 56 60 42 62
Localization
colon 42 52 .1484 39 47.5 .0166*
rectum 78 69 59 72
Tumor differentiation
G1 63 73 .2357 49 73.5 .2277
G2 + G3 57 52 49 53
Tumor size pT
pT2 12 75 7 71.5
pT3 72 71 61 70
pT4 36 40 30 42
pT2+pT3 v. pT4 71 v 40 .0005* 70 v 42 .0029*
Lymph node metastases pN
pN0 64 77 .0054* 46 75 .0338*
pN1 + pN2 56 45 52 49
Distant metastases
M0 101 74 .0000* 81 75 .0000*
M1 19 0 17 0
Dukes’ stage / TNM stage
A + B  / I° + II° 56 85 .00007* 38 86.5 .0003*
C + D  / III° + IV° 64 2 60 45
Radical surgical margin
yes 73 75 .0031* 61 74 .0066*
no 47 40 37 32.5
Vessel invasion
no 96 70 .0018* 78 67 .0584
yes 24 36 20 43
TS intensity
Low (0, 1) 43 74 .1896 35 75 .0908
High (2, 3) 77 55 63 52
TS pattern
Focal (0, 1) 50 82 .0024* 40 85 .0013*
Diffuse (2, 3) 70 48 58 43.7
* significant difference (P<.05)
Table III. Cox’s regression model m ultivariate analyses with respect to overall survival in the entire study population (n = 120) 
and in the group treated  with 5FU-based chemotherapy (n=98)
Parameter All patients 
n=120
Chemotherapy group 
n=98
HR** 95% CI P HR** 95% CI P
Localization
colon
rectum
1.0
1.91 1.12 -  2.70 .0452*
Tumor size pT 
pT2 + pT3 
pT4
1.0
1.82 1.43 -  2.22 .0028*
1.0
1.80 1.41 -  2.20 .0034*
TNM stage 
I° + II° 
III° + IV°
1.0
1.97 1.59 -  2.35 .0004*
1.0
6.52 5.30 -  7.74 .0026*
TS staining pattern  
F (focal; 0, 1)
D (diffuse; 2, 3)
1.0
2.36 1.56 -  3.16 .0355*
1.0
2.44 1.42 -  3.46 .0853
* significant difference (P < . 05)
** HR, hazard ratio (H R  = ep, where e=2.71828); CI, confidence interval
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* significant difference (p<0.05)
Figure 5. The 5-year overall survival curve for thymidylate synthase (TS) staining pattern  
(focal versus diffuse) for the study population (n=120)
* significant difference (p<0.05)
Figure 6. The 5-year overall survival curve for thymidylate synthase (TS) staining pattern  
(focal versus diffuse) for 98 patients treated with chemotherapy
treated with adjuvant 5-FU chemotherapy. The earlier 
observations of Edler and others in the group of colo­
rectal cancer patients with Dukes’ stage A-D revealed 
that 5-year overall survival of patients with high TS 
expression reached about 50% (in our study 48%) versus 
85% in patients with low TS level (82% in our study) 
[15].
Several previous reports have suggested that patients 
whose primary tum ors had low TS expression may be 
more sensitive to 5-FU-based chemotherapy [3, 4, 6, 9, 10, 
12, 13, 18-20, 22, 24].
There are also studies indicating that patients with 
high TS levels may benefit from adjuvant 5-FU chemo­
therapy [6]. In this retrospective investigation we found 
that patients with diffuse TS staining pattern  had the 
lesser but not significant benefit from the use of
5-FU chemotherapy compared with those patients 
whose tumors contained the focal TS staining pattern. 
However, the num ber of our patients in the chem o­
therapy group was relatively small.
Previous studies have demonstrated that in cases of 
disseminated disease the high TS mRNA level and the 
high TS protein expression assessed on the metastatic 
tumor indicated resistance to treatm ent based on 5-FU 
[11, 18, 20, 21]. Johnston et al. com pared the TS 
expression in the prim ary and m etastatic tum ors in 
colorectal cancer patients and found a lack of correlation 
between TS levels [3]. Aschele e t al. assessed TS 
expression immunohistochemically on the primary tumors 
and liver m etastases obtained from 18 patients with 
colorectal cancer [10]. In 11 of 18 patients the TS 
expression was different in primary and metastatic tumor, 
and in 10 patients the TS level was lower in the metastasis 
than in the primary site. Those results were observed only 
in patients with metastatic disease treated with fluoro- 
uracil. In our investigation among 98 patients treated  
with 5-FU only 17 had metastatic colorectal cancer (all 
with liver metastases). TS expression was assessed on the 
primary tumors. Similarly as in the study of Aschele et al., 
where the high TS levels were observed in primary tumors
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in 70 percent of patients, in our material the diffuse TS 
staining pattern was found in 13 of 17 patients treated 
with palliative chemotherapy (76.5%). The TS expression 
in the metastasis would be different than in the primary 
tum or, which could determ ine the response to 5-FU- 
based chemotherapy.
Gorlick et al. have demonstrated significantly higher 
TS expression in pulm onary m etastases than in liver 
metastases in advanced colorectal cancer [19]. Cascinu 
et al., on the contrary, have observed lower TS expression 
in liver metastases than in other abdominal metastases in 
patients with advanced colon cancer [12]. In addition, 
the investigation perform ed by Findlay and others has 
revealed that the TS level in the primary tumor could 
not serve as the predictor of response to 5FU-based 
chemotherapy in case of the disease dissemination [17].
Summarizing, the results of the above studies suggest 
that TS expression assessed on the primary tumor may 
not correlate with that measured in the metastasis of the 
same patient. Similar observation can relate to patients 
with locally advanced colorectal cancer, where the TS 
expression in the primary tumor may differ from the TS 
level on the site of micrometastases. So estimation of the 
TS expression in the primary tumor would not predict 
the response of m icrom etastases to the adjuvant 
chemotherapy.
Thus the issue of the optimal selection of patients for 
adjuvant treatm ent is still vague.
The results of our study suggest that the diffuse TS 
staining pattern  may help in the identification of high 
risk colorectal cancer patients who should receive more 
aggressive treatm ent. Such patients seem to be good 
candidates for chemotherapy regimens with irinotecan 
or oxaliplatin.
In conclusion, our study has confirmed the prog­
nostic value of the TS staining pattern  in colorectal 
cancer. Predictive role of TS expression assessed on the 
primary tumors still needs future investigations.
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